Humanized anti-VLA4 immunoglobulins
US7435802B2 · kind B2 · utility
11Cited by
1References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 8, 2004 |
| Grant date | Oct 14, 2008 |
| Priority date | — |
| Expiry date | Jan 28, 2026 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/7055
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.